Istituto Oncologico Veneto

Real‐World HRR Testing Pathways and Patterns of Detected Alterations in Prostate Cancer From the Multinational ARON‐3 Study

ABSTRACT Background Homologous recombination repair (HRR) testing is increasingly relevant in prostate cancer because it identifies patients who may benefit from biomarker‐guided treatment strategies, including poly(ADP‐ribose) polymerase inhibitors (PARPi). However, real‐world i...

VEGF pathway signalling across pulmonary neuroendocrine tumours: associations with histological subtypes in a multicentre study

Abstract The current classification of pulmonary neuroendocrine neoplasms (NENs) is primarily based on histomorphological criteria, which do not fully capture their underlying biological heterogeneity. This limitation is particularly evident among pulmonary carcinoids, a subgroup...

Sex and Mortality Among Patients with Papillary Thyroid Cancer

Importance Unlike patient age, which has been a well-established and routinely used primary biological prognostic factor in the risk stratification of papillary thyroid cancer (PTC), the prognostic value of patient sex remains controversial in this common endocrine malignant neop...

Neuroradiological spectrum of sarcoma intracranial metastases: a single center study

Sarcomas are a heterogeneous group of rare tumors sharing a common origin from connective or other non-epithelial tissues. Although clinical case series of intracranial sarcoma metastases have already been published, their neuroradiological findings are poorly known. This study a...

Circulating tumor DNA-guided de-escalation or escalation of adjuvant therapy in high-risk stage II and stage III colon cancer: the phase 2 PEGASUS trial

Oxaliplatin–fluoropyrimidine combinations are standard adjuvant therapy after radical resection of high-risk stage II and stage III colon cancer but expose many patients to toxicity while failing to prevent relapse in others. PEGASUS was a multicenter, single-arm, phase 2 trial e...

Longitudinal health-related quality of life after electrochemotherapy in elderly patients with cutaneous melanoma

The incidence of cutaneous melanoma (CM) is increasing among elderly patients, who often present with advanced disease, including cutaneous metastases. Electrochemotherapy (ECT) is a local ablative treatment that enhances chemotherapy uptake via electric pulses. Management in pat...

Comprehensive Clinicopathologic, Immunohistochemical, and Genomic Profiling of Sporadic Ampullary Somatostatin-producing D-cell Neuroendocrine Tumors Identifies Recurrent HRAS Hotspot Mutations

Abstract Ampullary somatostatin-producing D-cell neuroendocrine tumors are rare neoplasms that may be associated with type 1 neurofibromatosis. The molecular features of sporadic ampullary somatostatin-producing D-cell neuroendocrine tumors (SAMSOM-NETs) remain poorly characteriz...

Prognostic Role of Adverse Events in a Worldwide Population of Patients with Biliary Tract Cancer Treated with Chemo-Immunotherapy

Background: Biliary tract cancers (BTCs) are aggressive malignancies with limited treatment options. The addition of durvalumab or pembrolizumab to cisplatin–gemcitabine improves overall survival (OS), but validated biomarkers of benefit remain limited. Immune-mediated adverse ev...

Soft tissue sarcomas prognosis based on clinical-pathological profile: a retrospective population-based study

Soft tissue sarcomas (STSs) account for less than 1% of adult cancers and encompass a diverse range of neoplastic diseases. This population-based study evaluates the five-year overall survival rates of a cohort of STS patients. The study examined 325 incident cases of nonmetastat...

Severe Refractory Hypotension Following Patent Blue V Injection: A Case of Atypical Perioperative Anaphylaxis

Background and Clinical Significance: Patent Blue V (PBV) is widely used for sentinel lymph node mapping but may rarely cause severe hypersensitivity reactions. These reactions can present atypically, with predominant cardiovascular collapse and minimal cutaneous manifestations,...

Beyond Device Safety: Organisational Burden and Quality of Life in Oncology Outpatients with PICCs. A Descriptive Exploratory Study

Background and Objectives: Cancer care is increasingly delivered through outpatient pathways, thereby progressively transferring part of the organisational and practical workload of care to patients and informal caregivers. Although peripherally inserted central catheters (PICCs)...

Expert Consensus Develops Multidisciplinary Pathway for Cancer Pain Management in Italy: A Delphi Study

Background: Cancer pain remains highly prevalent and undertreated despite established guidelines. In Italy, Law 38/2010 mandates systematic pain assessment, yet only 26% of clinicians routinely evaluate pain at each clinical visit, and fewer than one-quarter have received formal...

Subtotal colectomy with antiperistaltic caecorectal anastomosis versus total colectomy with ileorectal anastomosis for refractory slow-transit constipation: a comparative analysis

Abstract In selected cases of slow-transit constipation (STC), total colectomy with ileorectal anastomosis (TC-IRA) remains the standard surgical treatment but is associated with heterogeneous outcomes and relevant functional sequelae. Subtotal colectomy with caecorectal anastomo...

Global Real‐World Outcomes of Olaparib in Metastatic Castration‐Resistant Prostate Cancer Patients With Homologous Recombination Repair Alterations

Evidence to guide the treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) and Homologous Recombination Repair (HRR) gene alterations outside of clinical trials remains limited. This was an observational, cohort study, including mCRPC patients with...

Real‐world outcomes of venetoclax plus hypomethylating agents in unfit acute myeloid leukaemia: Results of the GIMEMA AML2320 trial

Summary Venetoclax (VEN) plus hypomethylating agents (HMAs) represents the standard of care for newly diagnosed acute myeloid leukaemia (AML) patients unfit for intensive chemotherapy, but prospective real‐world observational data outside randomized clinical trials remain limited...